Z94.8
Conditions
Interventions
Group 1: Highly sensitized patients (preformed HLA antibodies, DSA or PRA = 90%) – recipients transplanted via the prioritized pancreas allocation program.
Group 2: Non-sensitized patients (no or low
Sponsors
Klinik für Viszeral-, Transplantations-, Thorax- und Gefäßchirurgie
Klinik für Allgemein- und Viszeralchirurgie Charité
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: •Patients who underwent pancreas transplantation between 2020 and 2025. •Participation in the Eurotransplant program for highly sensitized patients (HI listing) or assignment to the non-sensitized control group. •Availability of complete baseline clinical data (age, sex, blood group, BMI). •Documented immunological parameters (PRA level, DSA, HLA mismatch). •Availability of follow-up data for at least 90 days after transplantation.
Exclusion criteria
Exclusion criteria: •Patients with missing or incomplete baseline data (clinical or immunological parameters). •Missing follow-up data within the first 90 days after transplantation. •Retransplantations where assignment to HI or control group is not clearly possible. •Simultaneous or combined organ transplantations other than simultaneous pancreas-kidney transplantation (SPK), as SPK represents standard of care. •Patients who objected to the use of their data (if applicable).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 90-day pancreas graft survival (time-to-event): Time from transplantation to graft loss, defined as return to permanent insulin therapy, graft explantation, or patient death with a non-functioning graft; censoring at last follow-up within 90 days. | — |
Secondary
| Measure | Time frame |
|---|---|
| •1-year pancreas graft survival (time-to-event analysis). •Patient survival after transplantation (90 days and 1 year). •Causes of graft loss (e.g., thrombosis, acute cellular or antibody-mediated rejection, chronic rejection, surgical complications). •Acute rejection episodes, differentiated into cellular and antibody-mediated. •Primary versus delayed graft function. •Early pancreas graft thrombosis rate (within 30 days). •Impact of immunological parameters (PRA levels, donor specific antibodies [DSA], HLA mismatch) on graft survival and rejection risk. •Impact of immunosuppressive regimen (induction and maintenance therapy) on graft outcomes. | — |
Countries
Austria, Germany, Netherlands
Contacts
Public ContactFabian Haak
Klinik für Viszeral-, Transplantations-, Thorax- und Gefäßchirurgie
Outcome results
None listed